SpaceX’s $75B IPO Loses Ground as Galloway Targets GLP-1 Stocks
SPCX•SpaceX’s $75 billion IPO stands as the largest ever, yet its share price has declined since debut as investors question valuation and limited float. Scott Galloway recommends shifting capital to GLP-1 drug makers, highlighting Eli Lilly’s 418% stock gain since 2021 and its advancing phase 3 combination therapy.
1. Record-setting IPO and Declining Shares
On June 12, SpaceX launched a $75 billion IPO, the largest ever, but its share price has fallen below initial levels as constrained float and investor scrutiny of valuation weighed on trading.
2. Galloway’s GLP-1 Investment Thesis
Scott Galloway argues that GLP-1 therapies represent a superior opportunity, citing weight-loss drugs expanding into oncology and chronic disease. He notes Eli Lilly’s shares have surged 418% since 2021 and highlights a promising phase 3 combination therapy that could further drive growth.
